Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment

AIDS

Volumn 26, Issue 3, 2012, Pages 303-314

  Capeau, Jacqueline ^a   Bouteloup, Vincent ^b   Katlama, Christine ^c   Bastard, Jean Philippe ^a   Guiyedi, Vincent ^b   Salmon Ceron, Dominique ^d   Protopopescu, Camelia ^e   Leport, Catherine ^b   Raffi, Francois ^f   Chêne, Geneviève ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d CHU X Bichat ^*  (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f HÔTEL DIEU   (France)

Author keywords

diabetes mellitus; HIV infections; indinavir; lipodystrophy; stavudine

Indexed keywords

ANTIDIABETIC AGENT; ATAZANAVIR; DIDANOSINE; GLUCOSE; INDINAVIR; LOPINAVIR; NELFINAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AGING; ARTICLE; BODY MASS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INSULIN RESISTANCE; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADIPOSITY; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS; DIDANOSINE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; INDINAVIR; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STAVUDINE; WAIST-HIP RATIO;

EID: 84855346074     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834e8776     Document Type: Article

References (25)

1. Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther 2007; 12:149-162. (Pubitemid 46569900)
2. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50:499-505.
3. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-139. (Pubitemid 32150958)
4. Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34:1396-1405. (Pubitemid 34507951)
5. Rotger M, Gsponer T, Martinez R, Taffe P, Elzi L, Vernazza P, et al. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. Clin Infect Dis 2010; 51:1090-1098.
6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099. (Pubitemid 29278477)
7. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIVinfected women. J Acquir Immune Defic Syndr 2003; 32: 298-302. (Pubitemid 36331702)
8. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21:1739-1745. (Pubitemid 47237561)
9. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31:1224-1229.
10. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45:111-119. (Pubitemid 46984626)
11. Meisinger C, Thorand B, Schneider A, Stieber J, Doring A, Lowel H. Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Arch Intern Med 2002; 162:82-89. (Pubitemid 34073405)
12. Fagot-Campagna A, Romon I, Fosse S, Roudier C. 'Prevalence and incidence of diabetes and diabetes-related mortality in France' Report InVS. In. Saint-Maurice, France: InVS (Institut de Veille Sanitaire); 2010. pp. 1-12.
13. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160-3167. (Pubitemid 37339514)
14. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21:2445-2453. (Pubitemid 350145176)
15. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-1645.
16. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184. (Pubitemid 40720744)
17. Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study.. Am J Clin Nutr 2006; 84:483-489. (Pubitemid 44713396)
18. Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, et al. Hepatitis C is associated with type 2 diabetes mellitus in HIVinfected persons without traditional risk factors. HIV Med 2007; 8:491-497. (Pubitemid 47616827)
19. Howard AA, Floris-Moore M, Lo Y, Arnsten JH, Fleischer N, Klein RS. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med 2006; 7:389-396. (Pubitemid 44123250)
20. Howard AA, Hoover DR, Anastos K, Wu X, Shi Q, Strickler HD, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2010; 54:152-159.
21. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010; 33:2244-2249.
22. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009; 94:3171-3182.
23. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004; 53:1782-1789. (Pubitemid 38857036)
24. Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV/AIDS Rep 2005; 2:39-50.
25. Lo YC, Chen MY, Sheng WH, Hsieh SM, Sun HY, Liu WC, et al. Risk factors for incident diabetes mellitus among HIVinfected patients receiving combination antiretroviral therapy in Taiwan: a case-control study. HIV Med 2009; 10:302-309.